通用名称为FUSILEV
Levoleucovorin(硫酸钠钙)50mg/vial;配制后静脉注射PWD;含有甘露醇50mg/vial; 175mg/17.5mL,250mg/25mL静脉注射soln,不含防腐剂。
法律分类:
接收
类药物为FUSILEV
叶酸类似物。
制造商的FUSILEV
光谱制药公司
主治为FUSILEV
先进的转移性结直肠癌姑息治疗相结合,与5 - 氟尿嘧啶(5 - FU)。
成人剂量为FUSILEV
管理levoleucovorin和5 - FU分别以避免沉淀物的形成。养生之1:缓慢静脉注射给予levoleucovorin在100mg/m2至少超过3分钟,5 - 氟尿嘧啶370mg/m2静脉注射。养生2:给levoleucovorin在10mg/m2,静脉注射,随后在425mg/m2静脉注射5 - FU。两种:治疗每天为5天。为期五天的治疗过程中可能会重复在4个星期(28天)2个疗程的间隔,然后在4-5周(28-35天),从以前的治疗过程中的毒副作用完全恢复病人的时间间隔反复。随后的治疗过程中的剂量调整:看到文学。
儿童剂量为FUSILEV
不推荐。
为FUSILEV警告/注意事项
不适用于治疗恶性贫血和巨幼细胞性贫血。老人。虚弱。怀孕(Cat.C)。哺乳的母亲。
为FUSILEV的相互作用
Potentiates 5 - 氟尿嘧啶的毒性。拮抗TMP / SMZ。拮抗抗惊厥药(如苯巴比妥,扑米酮,苯妥英)。可能受药物影响甲氨蝶呤消除。
FUSILEV的不良反应
口腔炎,恶心,腹泻。
如何FUSILEV提供?
单次使用小瓶(PWD,soln)-1
FUSILEV™ (levoleucovorin,注射用左旋亚叶酸)
Generic Name for FUSILEVLevoleucovorin (as calcium pentahydrate) 50mg/vial; pwd for IV inj after reconstitution; contains mannitol 50mg/vial; 175mg/17.5mL, 250mg/25mL; soln for IV inj; preservative-free. Legal Classification:Rx Pharmacological Class for FUSILEVFolate analogue. Manufacturer of FUSILEVSpectrum Pharmaceuticals, Inc. Indications for FUSILEVPalliative treatment of advanced metastatic colorectal cancer in combination with 5-fluorouracil (5-FU). Adult dose for FUSILEVAdminister levoleucovorin and 5-FU separately to avoid precipitate formation. Regimen 1: give levoleucovorin at 100mg/m2 by slow IV inj over a minimum of 3 minutes, followed by 5-FU at 370mg/m2 by IV inj. Regimen 2: give levoleucovorin at 10mg/m2 by IV inj, followed by 5-FU at 425mg/m2 by IV inj. Both: Treat daily for 5 days. Five-day treatment course may be repeated at 4 week (28 days) intervals for 2 courses, and then repeated at 4–5 week (28–35 days) intervals provided that patient recovered completely from toxic effects from prior treatment course. Dose adjustments for subsequent treatment course: see literature. Children's dosing for FUSILEVNot recommended. Warnings/Precautions for FUSILEVNot for treating pernicious anemia and megaloblastic anemia. Elderly. Debilitated. Pregnancy (Cat.C). Nursing mothers. Interactions for FUSILEVPotentiates 5-fluorouracil toxicity. Antagonizes TMP/SMZ. Antagonizes anticonvulsants (eg, phenobarbital, primidone, phenytoin). May be affected by drugs that affect MTX elimination. Adverse Reactions for FUSILEVStomatitis, nausea, diarrhea. How is FUSILEV supplied?Single-use vial (pwd, soln)—1 FUSILEV (levoleucovorin)注射剂用于转移性结直肠癌新药 |